Newsletter
Every new paper in this field, in your inbox.
Researchers evaluated a sarcoma DNA methylation classifier for soft tissue and bone tumors, including 619 cases. The classifier exhibited high sensitivity and specificity for fusion sarcomas (Ewing, synovial, cic-rearranged, bcor-rearranged), leiomyosarcoma, MPNST, and malignant vascular tumors. However, sensitivity was low for desmoid fibromatosis, neurofibroma, and…
In the quest for effective gastroenteropancreatic neuroendocrine carcinoma treatments, researchers unleashed patient-derived tumor spheroids. A dazzling 16 compounds, notably tyrosyl-DNA phosphodiesterase 1 inhibitors, emerged as fierce warriors against over 75% of these rare tumors. Cytarabine, a standout from the bunch, synergized with standard drugs, intensifying…
Researchers delved into the battle of surgical approaches for benign retroperitoneal tumors (BRTs). Analyzing data from 43 patients, the laparoscopic transperitoneal approach emerged as the superhero, boasting lower conversion rates and comparable outcomes to its retroperitoneal counterpart. With enhanced visual perspectives and bleeding control, the…
This study dives into the world of high-grade soft tissue sarcoma, a rare and challenging condition. Researchers at a southeastern U.S. cancer center examined racial and ethnic variations in patient presentation and outcomes. Black patients represented a higher percentage than national averages, with differences in…
This study delved into the rare world of mixed neuroendocrine-non-neuroendocrine neoplasms in colorectal cancer and their more aggressive counterpart, neuroendocrine carcinomas. They found that adjuvant chemotherapy significantly improved survival for patients with stage III mixed neuroendocrine-non-neuroendocrine neoplasms and neuroendocrine carcinomas. The median survival for these…
Neoadjuvant imatinib, a treatment for gastrointestinal stromal tumors (GISTs), effectively and safely decreases tumor size, enabling less extensive surgery with a higher rate of complete resection. Among 108 GIST patients, 88% experienced reduced tumor size. Those with specific genetic mutations predicted a positive response to…
In a data-driven investigation involving 991 primary gastrointestinal melanoma patients, researchers constructed reliable prognostic models for predicting overall survival (OS) and cancer-specific survival (CSS). These models incorporated key factors like age, disease stage, lymph node density, and surgery. Rigorous testing confirmed their effectiveness, making them…
Centralizing surgical care, this study investigated small intestinal neuroendocrine tumor (SI-NET) resections' outcomes based on procedure volume. High-volume centers (HVCs) performed over five SI-NET resections annually, while low-volume centers (LVCs) did fewer. HVCs showcased better surgical quality, with more lymph nodes resected, advanced techniques, and…
